TY - JOUR
T1 - Defining routine fatigue care in Multiple Sclerosis in the United Kingdom
T2 - What treatments are offered and who gets them?
AU - Picariello, Federica
AU - Freeman, Jennifer
AU - Moss-Morris, Rona
N1 - Funding Information:
We would like to thank our PPI advisory group for helping us design the fatigue treatments offered questionnaire. We would also like to thank the UKMSR team for helping with the day-to-day management of data collection. The authors disclose receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Penelope and Eugene Rosenberg award via donation through Guy's and St Thomas? Charity (R160601 Rosenberg Funding) and the MS Society. RMM acknowledges the financial support of the Department of Health via the National Institute for Health Research (NIHR) Specialist Biomedical Research Centre for Mental Health award to the South London and Maudsley NHS Foundation Trust (SLaM) and the Institute of Psychiatry at King's College London. The views expressed in this article are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. The funders had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The authors had access to all study data and final responsibility for the decision to submit for publication.
Funding Information:
The authors disclose receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Penelope and Eugene Rosenberg award via donation through Guy's and St Thomas’ Charity (R160601 Rosenberg Funding) and the MS Society. RMM acknowledges the financial support of the Department of Health via the National Institute for Health Research (NIHR) Specialist Biomedical Research Centre for Mental Health award to the South London and Maudsley NHS Foundation Trust (SLaM) and the Institute of Psychiatry at King's College London. The views expressed in this article are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. The funders had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The authors had access to all study data and final responsibility for the decision to submit for publication.
Publisher Copyright:
© The Author(s), 2022.
PY - 2022/1
Y1 - 2022/1
N2 - Background: Fatigue is common and disabling in Multiple Sclerosis (MS). A recent meta-analytic systematic review reported 113 trials of exercise and behavioural interventions for fatigue, yet patients consistently describe fatigue being under-treated. The extent of the research-to-practice gap is yet to be documented. Objective: To describe what fatigue treatments people with MS (pwMS) in the United Kingdom (UK) have been offered. Methods: A cross-sectional survey of pwMS on the UK MS Register (UKMSR). Data on fatigue treatments offered were collected using an online questionnaire developed with patient input and summarised using descriptive statistics. Sociodemographic, MS-related, and psychological factors associated with treatment offered were evaluated using a logistic regression model. Results: 4,367 respondents completed the survey, 90.3% reported experiencing fatigue. Of these, 30.8% reported having been offered at least one type of pharmacological/non-pharmacological treatment for fatigue. Pharmacological treatments were more commonly offered (22.4%) compared to non-pharmacological treatments (12.6%; 2.9% exercise and 5.9% behavioural therapy). In the logistic regression model, older age, working, shorter time since MS diagnosis, and lower fatigue were associated with lower odds of having been offered treatment for fatigue. Conclusion: This study accentuates the extent of the unmet need for fatigue treatment in MS in the UK.
AB - Background: Fatigue is common and disabling in Multiple Sclerosis (MS). A recent meta-analytic systematic review reported 113 trials of exercise and behavioural interventions for fatigue, yet patients consistently describe fatigue being under-treated. The extent of the research-to-practice gap is yet to be documented. Objective: To describe what fatigue treatments people with MS (pwMS) in the United Kingdom (UK) have been offered. Methods: A cross-sectional survey of pwMS on the UK MS Register (UKMSR). Data on fatigue treatments offered were collected using an online questionnaire developed with patient input and summarised using descriptive statistics. Sociodemographic, MS-related, and psychological factors associated with treatment offered were evaluated using a logistic regression model. Results: 4,367 respondents completed the survey, 90.3% reported experiencing fatigue. Of these, 30.8% reported having been offered at least one type of pharmacological/non-pharmacological treatment for fatigue. Pharmacological treatments were more commonly offered (22.4%) compared to non-pharmacological treatments (12.6%; 2.9% exercise and 5.9% behavioural therapy). In the logistic regression model, older age, working, shorter time since MS diagnosis, and lower fatigue were associated with lower odds of having been offered treatment for fatigue. Conclusion: This study accentuates the extent of the unmet need for fatigue treatment in MS in the UK.
KW - Amantadine
KW - behavioural interventions
KW - exercise interventions
KW - Fatigue
KW - implementation
KW - multiple sclerosis
KW - routine care
KW - UKMSR
UR - http://www.scopus.com/inward/record.url?scp=85123436003&partnerID=8YFLogxK
U2 - 10.1177/20552173211072274
DO - 10.1177/20552173211072274
M3 - Article
AN - SCOPUS:85123436003
SN - 2055-2173
VL - 8
JO - Multiple sclerosis journal - experimental, translational and clinical
JF - Multiple sclerosis journal - experimental, translational and clinical
IS - 1
ER -